Advice

following an abbreviated submission:

latanoprost plus timolol (Fixapost®) is accepted for restricted use within NHSScotland.

Indication under review: reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

SMC restriction: to use in patients who have proven sensitivity to preservatives.

The combination product costs less than preservative-free latanoprost and timolol eye drops administered separately but is more expensive than the equivalent generic multi-dose eye drop preparation with preservative.

Download detailed advice361KB (PDF)

Download

Medicine details

Medicine name:
latanoprost + timolol (Fixapost)
SMC ID:
SMC2159
Indication:
Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Pharmaceutical company
Thea Pharmaceuticals
BNF chapter
Submission type
Abbreviated
Status
Restricted
Date advice published:
13 May 2019